Search - tctmd.com

Displaying 281 - 300 of 457

Sort: Relevancy | Date

FOURIER Surveys Reassure About Cognitive Safety of Evolocumab

News Daily News

FOURIER Surveys Reassure About Cognitive Safety of Evolocumab

May 06, 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

Hope for these hard-to-treat patients: more than half saw ≥ 50% decrease at 24 weeks, regardless of LDL receptor function.

News Conference News ACC 2020

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Yael L. Maxwell

April 01, 2020

Low Mortality Rates Seen With Andexanet Alfa for Factor Xa-Related Bleeds

News Conference News ACC 2020

Low Mortality Rates Seen With Andexanet Alfa for Factor Xa-Related Bleeds

March 25, 2020

News Daily News

COVID-19 Should Not Guide Use of ACE Inhibitors/ARBs, Heart Societies Say

March 17, 2020

Telehealth Program Helps Minority Stroke Survivors Control BP

News Conference News ISC 2020

Telehealth Program Helps Minority Stroke Survivors Control BP

February 26, 2020

News Daily News

Long-term Evolocumab Safe, Effective for Familial Hypercholesterolemia Treatment

Yael L. Maxwell

February 12, 2020

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

News Daily News

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

Michael O'Riordan

February 10, 2020

Trials of New Cancer Drugs Failing to Address Potential CV Risks

News Daily News

Trials of New Cancer Drugs Failing to Address Potential CV Risks

February 10, 2020

Pot Talk: Review Urges Cardiologists to Discuss Marijuana Use

News Daily News

Pot Talk: Review Urges Cardiologists to Discuss Marijuana Use

January 21, 2020

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

News Daily News

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Michael O'Riordan

January 14, 2020

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

AHA Plugs ‘Dietary Patterns’ Over Dietary Cholesterol Targets

News Daily News

AHA Plugs ‘Dietary Patterns’ Over Dietary Cholesterol Targets

Yael L. Maxwell

December 26, 2019

Non-HDL Cholesterol Strongly Tied to Lifetime CVD Risk

News Daily News

Non-HDL Cholesterol Strongly Tied to Lifetime CVD Risk

Michael O'Riordan

December 03, 2019

LDL Levels Still Too High in Many Statin-Treated Patients: PINNACLE

News Conference News AHA 2019

LDL Levels Still Too High in Many Statin-Treated Patients: PINNACLE

Michael O'Riordan

November 13, 2019

Lipid Levels Declining in US, With Drops Seen After 2013 Guideline Release

News Daily News

Lipid Levels Declining in US, With Drops Seen After 2013 Guideline Release

Michael O'Riordan

November 11, 2019

Evolocumab Safe and Effective Out to 5 Years: OSLER-1

News Daily News

Evolocumab Safe and Effective Out to 5 Years: OSLER-1

Yael L. Maxwell

October 22, 2019

Recurrent Events Common Among Young Patients With CAD

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

Drug Abuse in Infective Endocarditis Patients Spikes Amid US Opioid Epidemic

News Daily News

Drug Abuse in Infective Endocarditis Patients Spikes Amid US Opioid Epidemic

October 02, 2019

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

News Daily News TCT 2019

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

October 02, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.